Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-In-Man, Phase I, Single-Blind, Placebo-Controlled, Ascending Single Dose Study of Intravenous YQ23 in Healthy Male and Female Subjects to Assess Safety, Tolerability, and Pharmacokinetics

Next Previous
Trial Profile

First-In-Man, Phase I, Single-Blind, Placebo-Controlled, Ascending Single Dose Study of Intravenous YQ23 in Healthy Male and Female Subjects to Assess Safety, Tolerability, and Pharmacokinetics

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YQ 23 (Primary)
  • Indications Cancer; Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors New Beta Innovation

Most Recent Events

  • 01 Mar 2021 Status changed from active, no longer recruiting to completed.
  • 13 Oct 2020 Status changed from recruiting to active, no longer recruiting.
  • 18 Aug 2020 Planned primary completion date changed from 3 Aug 2020 to 30 Sep 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top